Patent ID: 9109035
Filing Date: 2015-08-18
Classification: A61K,A61P,C07K,C12N

Abstract:
1. A method of treating a cell proliferative disorder comprising cells that express TAT226, comprising administering to an individual having said disorder an effective amount of an antibody that binds to TAT226, or antigen-binding fragment thereof, wherein the antibody comprises: a heavy chain variable domain comprising a HVR-H1 comprising the amino acid sequence of SEQ ID NO:4, a HVR-H2 comprising the amino acid sequence of SEQ ID NO:5, and a HVR-H3 comprising an amino acid sequence selected from SEQ ID NO:6-10; a light chain variable domain comprising a HVR-L1 comprising the amino acid sequence of SEQ ID NO:12, a HVR-L2 comprising the amino acid sequence of SEQ ID NO:13, and a HVR-L3 comprising an amino acid sequence selected from SEQ ID NO:14-18, wherein the antibody or antigen-binding fragment thereof is covalently attached to a cytotoxic agent to form an antibody-drug conjugate.